NEW YORK (GenomeWeb News) – DioGenix announced today a collaboration with Fast Forward to develop a molecular diagnostic test for multiple sclerosis.

As part of the deal, Fast Forward, a subsidiary of the National Multiple Sclerosis Society, will provide DioGenix $500,000 to expand its ongoing clinical trial for MSPrecise, a diagnostic test based on next-generation sequencing to measure genetic mutations in the adaptive immune system by analyzing B cells isolated from cerebral spinal fluid.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: variant linked to canine cleft lip, new compression tool, and more.

GNC will start using DNA testing to authentic the presence of plants included in its labels, following an agreement with the New York Attorney General.

Fareed Zakaria writes that instead of focusing solely on STEM-related courses, students would do well to pursue the liberal arts if they want to be technology innovators.

A Harvard Business Review study found four major patterns of gender biases and added that black and Latina scientists further had to navigate racial stereotypes.

Apr
15
Sponsored by
WaferGen

This live online seminar will highlight recent trends in applying next-generation sequencing in the clinical setting, with a particular focus on oncology and rare disease.